Early detection. Proven momentum.
Pancreatic cancer has the lowest survival rate of any major cancer; with a five-year survival rate of just 13%. The key reason is that it’s almost always found too late. Immunovia's diagnostic test PancreaSure is an accurate and easy-to-use blood test, validated in three published clinical studies, that detects pancreatic cancer at Stage I and II, when the odds of survival are highest.
Commercializing PancreaSure
Over 2.7 million Americans are at high risk of pancreatic cancer and meet criteria for annual testing. Since its launch, PancreaSure has been adopted by leading US cancer surveillance programmes. Next, focus lies on higher usage and test volumes.
Read about Immunovia's commercialization strategy
The science behind PancreaSure
In three peer-reviewed studies, PancreaSure has detected early-stage pancreatic cancer with market-leading accuracy. The results are published in respected scientific journals and Immunovia's clinical development continues to build clinical validity.
Read about the science of PancreaSure
Reimbursement
Payment for PancreaSure can come via three channels: the patient, private insurance companies, and the US public health insurance system Medicare. Today, patients and insurance companies pay, while Immunovia aims to obtain Medicare reimbursement.
Read about Immunovia's routes to coveragePress releases
Here you can find our latest press releases and company news – all gathered in one place for easy access.
Financial reports
Here you can find Immunovia’s quarterly reports, annual reports and year-end reports, compiled for investors and the capital markets.